2,791 results match your criteria Antiphospholipid Antibody Syndrome and Pregnancy


Thrombophilia, risk factors and prevention.

Expert Rev Hematol 2019 Feb 18. Epub 2019 Feb 18.

a Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine (DIMED), Padova University Hospital , Italy.

Introduction: Fifty-three years after the first description of an inherited prothrombotic condition (antithrombin deficiency), our knowledge on hereditary and acquired causes of hypercoagulability that can predispose carriers to venous thromboembolism (VTE) has greatly improved. Areas covered: Main causes of hereditary thrombophilia are summarized alongside new prothrombotic mutations recently discovered. The main causes of acquired thrombophilia, and namely, antiphospholipid antibody syndrome and hyperhomocysteinemia, are also discussed together with other common acquired prothrombotic states characterized by an increase of procoagulant factors and/or a decrease of natural anticoagulants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583555DOI Listing
February 2019

The European registry on obstetric Antiphospholipid syndrome (EUROAPS): A survey of 1000 consecutive cases.

Autoimmun Rev 2019 Feb 14. Epub 2019 Feb 14.

Obstetrics and Gynaecology Department, High Risk Unit, Vall d'Hebron University Hospital, Universitat Autonoma, Barcelona, Spain.

Aim To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them up on a cohort of 1000 women with obstetric antiphospholipid syndrome (OAPS).

Methods: The European Registry of OAPS became a registry within the framework of the European Forum on Antiphospholipid Antibody projects and was placed on a website in June 2010. Thirty hospitals throughout Europe have collaborated to carry out this registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.12.006DOI Listing
February 2019

Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.

Curr Opin Rheumatol 2019 Feb 11. Epub 2019 Feb 11.

Division of Rheumatology, Department of Internal Medicine, University of Michigan.

Purpose Of Review: Although antiphospholipid syndrome (APS) is best known for conveying increased risk of thrombotic events and pregnancy morbidity, thrombocytopenia is also recognized as a common association. In this review, we will explore the relationship between thrombocytopenia and APS, highlighting our evolving understanding - and persistent knowledge gaps - through clinically oriented questions and answers.

Recent Findings: A history of thrombocytopenia likely portends a more severe APS phenotype (including increased risk of thrombosis). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000595DOI Listing
February 2019
1 Read

Outcomes of Pregnancy in Women With Inflammatory Myositis: A Retrospective Cohort From India.

J Clin Rheumatol 2019 Feb 1. Epub 2019 Feb 1.

From the Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.

Objectives: Idiopathic inflammatory myositis (IIM) commonly affects women in the childbearing age group. Both disease activity and immunosuppressants used may have adverse effects on fertility and outcomes of pregnancy. We explored these outcomes in a retrospective cohort of women with IIM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000996DOI Listing
February 2019
3 Reads

Laboratory Diagnostics in Thrombophilia.

Hamostaseologie 2019 Feb 31;39(1):49-61. Epub 2019 Jan 31.

Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.

A thrombophilic disorder is a hereditary or acquired condition that increases the risk of thrombosis. The most common hereditary thrombophilias that predispose to venous thrombosis in the Caucasian population are the heterozygous forms of the factor V Leiden and prothrombin G20210A mutation that are generally detected by direct DNA genotyping. Immunologic antigen assays and chromogenic or clot-based activity assays are used to identify deficiencies in the natural coagulation inhibitors antithrombin, protein C and protein S. Read More

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0039-1677840
Publisher Site
http://dx.doi.org/10.1055/s-0039-1677840DOI Listing
February 2019
8 Reads

In vitro fertilization and autoimmunity: Evidence from an observational study.

Eur J Obstet Gynecol Reprod Biol 2019 Jan 14;234:137-142. Epub 2019 Jan 14.

"Sapienza", Università di Roma, Dipartimento di Medicina Clinica e Molecolare, Facoltà di Medicina e Psicologia, Ospedale Sant'Andrea, Via Grottarossa 1035-1039, 00189, Roma, Italy. Electronic address:

Introduction: The aim of this study was to evaluate the prevalence of antiphospholipid antibodies (aPLs) in infertile women undergoing in vitro fertilization (IVF).

Method Of Study: From January 2012 to December 2017, 520 consecutive clinical records of infertile women undergoing IVF were evaluated. Among them, 100 consecutive clinical records of patients with positive autoantibodies were selected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2018.12.042DOI Listing
January 2019

Timing of initiation of low-molecular-weight heparin administration in pregnant women with antiphospholipid syndrome: a randomized clinical trial of efficacy and safety.

Int J Womens Health 2019 14;11:41-47. Epub 2019 Jan 14.

Department of Obstetrics and Gynecology, Mansoura University, Mansoura, Egypt,

Objective: We aimed to evaluate the effect of different timing of initiation of low-molecular-weight heparin (LMWH) administration on the pregnancy outcomes in women with antiphospholipid syndrome (APS).

Materials And Methods: A randomized controlled study was conducted on women with obstetrical APS. All participants were randomly divided at documentation of positive pregnancy test into two groups; early initiation group in which LMWH therapy was started once positive pregnancy test was established (in the fifth week of gestation), and later initiation group in which LMWH therapy was started after sonographic confirmation of fetal cardiac pulsation (in the seventh week of gestation). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJWH.S193293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336021PMC
January 2019
1 Read

Cerebral Venous Sinus Thrombosis in Systemic Lupus Erythematosus.

Acta Med Indones 2018 Oct;50(4):343-345

Department of Internal Medicine, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia.

A 38-year-old woman presented with general weakness and vaginal bleeding. One month prior, she had been diagnosed with Evans syndrome (haemolytic anemia with positive Coombs test and thrombocytopenia) and was given oral steroid as maintenance therapy. Her serology examination was negative for hepatitis B, hepatitis C, and human immunodeficiency virus (HIV). Read More

View Article

Download full-text PDF

Source
October 2018
9 Reads

Mechanisms of Endothelial Dysfunction in Antiphospholipid Syndrome: Association With Clinical Manifestations.

Front Physiol 2018 21;9:1840. Epub 2018 Dec 21.

Grupo Reproducción, Departamento de Microbiología y Parasitología, Escuela de Medicina, Universidad de Antioquia, Medellín, Colombia.

The endothelium is a monolayer of cells that covers the inner surface of blood vessels and its integrity is essential for the maintenance of vascular health. Endothelial dysfunction is a key pathological component of antiphospholipid syndrome (APS). Its systemic complications include thrombotic endocarditis, valvular dysfunction, cerebrovascular occlusions, proliferative nephritis, deep vein thrombosis, and pulmonary embolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphys.2018.01840DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309735PMC
December 2018
3 Reads

Management of pregnant women with antiphospholipid antibodies.

Expert Rev Clin Immunol 2019 Jan 8. Epub 2019 Jan 8.

a Rheumatology Unit, Department of Medicine , University Hospital of Padua , Via Giustiniani, 2, 35128 Padua , Italy.

Introduction: Important advancements in pregnancy outcome have been reported in women with antiphospholipid antibodies (aPL), despite the fact that the treatment of aPL related pregnancy morbidity is not guided by consistent findings from well-designed trials. Areas covered: The current study draws a picture of the studies in the literature by performing a Medline search of relevant English language articles and reports our experience in managing different subsets of obstetric antiphospholipid syndrome (APS), defined on the basis of their clinical and laboratory characteristics. The management of pregnant women with non-criteria APS manifestations and that of aPL carriers during their first pregnancy is also examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1565995DOI Listing
January 2019
2 Reads

[Comparison of the etiological constitution of two and three or more recurrent miscarriage].

Zhonghua Fu Chan Ke Za Zhi 2018 Dec;53(12):855-859

Center for Reproductive Medicine, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.

To compare the etiological constitution of recurrent miscarriage (RM) between patients with consecutive two and three or more miscarriages through combining the routine examination results and embryonic karyotype. Patients with a history of two or more consecutive clinical miscarriages (≤12 weeks of gestation) consulting in the RM clinic of the First Affiliated Hospital of Sun Yat-sen University from March 2011 to January 2016 were collected. Six hundred and ninety-six with detailed history recorded, routine clinical examinations of RM and at least once embryonic karyotype were ultimately enrolled in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-567x.2018.12.010DOI Listing
December 2018
2 Reads

Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome.

Tuberc Respir Dis (Seoul) 2019 Jan;82(1):53-61

Department of Pulmonary and Critical Care Medicine, Center for Pulmonary Hypertension and Venous Thrombosis, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Background: Antiphospholipid antibody syndrome (APS), an important cause of acquired thrombophilia, is diagnosed when vascular thrombosis or pregnancy morbidity occurs with persistently positive antiphospholipid antibodies (aPL). APS is a risk factor for unprovoked recurrence of pulmonary embolism (PE). Performing laboratory testing for aPL after a first unprovoked acute PE is controversial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4046/trd.2018.0045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304333PMC
January 2019
1 Read

[Increased serum soluble-endoglin level and its clinical significance in antiphospholipid syndrome].

Beijing Da Xue Xue Bao Yi Xue Ban 2018 Dec;50(6):1027-1032

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.

Objective: To detect the serum levels of soluble endothelial glycoprotein endoglin (s-Eng) in patients with antiphospholipid syndrome (APS) and to evaluate the correlation between s-Eng levels and clinical features and laboratory parameters.

Methods: The levels of serum s-Eng were measured by enzyme linked immunosorbent assay (ELISA) in 139 patients with APS, 44 patients with SLE but no APS, 37 patients with primary Sjögren's syndrome (pSS), 23 patients with Bechet's disease (BD), 22 patients with systemic sclerosis (SSc) and 22 persistent anticardiolipin antibody (aCL) positive individuals without SLE or APS (simply aCL positive group) and 87 health controls (HC) without any auto-immune diseases. These APS patients included 64 primary APS patients and 75 APS patients secondary to SLE. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

[Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome].

Beijing Da Xue Xue Bao Yi Xue Ban 2018 Dec;50(6):956-961

Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China.

Recurrent spontaneous abortion is one of the common complications in women of childbearing age during pregnancy. The immune factor accounts for a large proportion of many causes. Antiphospholipid antibody syndrome is the most common type of acquired thrombophilia disease. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome.

Front Pediatr 2018 27;6:362. Epub 2018 Nov 27.

Department of Rheumatology, University College London, London, United Kingdom.

Antiphospholipid syndrome (APS) is a rare autoimmune disease of unknown etiology that represents a leading cause of acquired thromboembolism and recurrent miscarriage. It is characterized by the persistent elevated presence of pathogenic antiphospholipid auto-antibodies directed against cardiolipin, ß2-glycoprotein-I, and/or a positive lupus anticoagulant test. As with many autoimmune disorders, the pathogenesis of APS is believed to be the result of a complex interaction between environmental triggers and genetic predisposition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2018.00362DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277799PMC
November 2018
1 Read

Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome.

Front Immunol 2018 20;9:2644. Epub 2018 Nov 20.

Immunology Department, Hospital 12 de Octubre, Madrid, Spain.

Antiphospholipid syndrome (APS) is an acquired autoimmune disorder defined by the presence of both clinical (thromboembolic events or pregnancy morbidity) and laboratory (antiphospholipid antibodies, aPL) manifestations. Despite their importance, several clinical manifestations strongly associated with APS such as livedo reticularis (LR), thrombocytopenia, sicca-ophthalmic(sicca), heart, or neurological manifestations are not included in the APS clinical classification criteria. Circulating immune complexes (CIC) formed by Beta-2-glycoprotein I (B2GPI) and aPL (B2-CIC) have been described and their presence has been related with thrombotic events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.02644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256181PMC
November 2018
11 Reads

Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.

Front Neurol 2018 26;9:1001. Epub 2018 Nov 26.

Section of Neurology, Department of Translational Medicine University of Eastern Piedmont, Novara, Italy.

Antiphospholipid syndrome (APS) is an autoimmune antibody-mediated condition characterized by thrombotic events and/or pregnancy morbidity in association with persistent positivity to antiphospholipid antibodies (aPL). The nervous system is frequently affected, as intracranial vessels are the most frequent site of arterial pathology. Over the course of years, many other neurological conditions not included in the diagnostic criteria, have been associated with APS. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fneur.2018.01001
Publisher Site
http://dx.doi.org/10.3389/fneur.2018.01001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275383PMC
November 2018
5 Reads

Post-partum catastrophic antiphospholipid syndrome presenting with shock and digital ischaemia - A diagnostic and management challenge.

J Intensive Care Soc 2018 Nov 19;19(4):357-364. Epub 2018 Mar 19.

Intensive Care Medicine, Nepean Hospital, Kingswood, NSW, Australia.

Catastrophic antiphospholipid syndrome is a rare multisystem autoimmune condition characterised by rapid development of widespread thrombotic disease and subsequent multi-organ failure. It is the most severe complication of antiphospholipid syndrome, carrying significant morbidity and mortality. We report a patient with post-partum catastrophic antiphospholipid syndrome with cardiac, hepatic, renal and cutaneous manifestations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1751143718762343DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259081PMC
November 2018
2 Reads

Anti-phospholipid Antibody Syndrome Presenting as Huge Ascites: A Case Report.

Mymensingh Med J 2018 Oct;27(4):883-887

Dr Abed Hussain Khan, Assistant Professor, Department of Internal Medicine, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.

Antiphospholipid Syndrome (APS) is characterized by arterial, venous or small vessel thromboses and/or pregnancy morbidity in the presence of persistently elevated titers of antiphospholipid antibodies. Since virtually any organ can be involved, the clinical presentation of APS is very varied. Abdominal manifestations are rare but may be life-threatening, and include Budd-Chiari Syndrome. Read More

View Article

Download full-text PDF

Source
October 2018
3 Reads

Genome-wide DNA methylation analysis in primary antiphospholipid syndrome neutrophils.

Clin Immunol 2018 Nov 22;196:110-116. Epub 2018 Nov 22.

Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA. Electronic address:

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thromboembolic events and pregnancy loss. We sought to characterize the DNA methylation profile of primary APS in comparison to healthy controls and individuals with SLE. In primary APS neutrophils compared to controls, 17 hypomethylated and 25 hypermethylated CpG sites were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2018.11.011DOI Listing
November 2018
9 Reads

Antiphospholipid syndrome in obstetrics.

Authors:
M Kemp W Thomas

Lupus 2018 Oct;27(1_suppl):28-31

2 Department of Haematology, Haemophilia & Thrombophilia Centre, Addenbrooke's Hospital, Cambridge, UK.

Antiphospholipid syndrome (APS) covers a spectrum of clinical manifestations ranging from recurrent pregnancy loss and obstetric complications from placental dysfunction through to thrombotic disease. This article will focus on the common manifestations of the pregnancy-related complications of APS. This includes clinical manifestations, diagnosis and management, as general practitioners will need to be able to recognize the disorder and will also have patients under their care receiving treatment for APS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203318801664DOI Listing
October 2018
4 Reads

Thrombotic antiphospholipid syndrome.

Authors:
S Sciascia M Radin

Lupus 2018 10;27(1_suppl):21-27

1 Center of Research of Immunopathology and Rare Diseases - Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203318801686DOI Listing
October 2018
1 Read

New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats.

Haematologica 2018 Nov 15. Epub 2018 Nov 15.

Istituto Auxologico Italiano,IRCCS, Milan, Italy;

Clinical studies have reported different diagnostic/predictive values of antibodies to domain 1 or 4/5 of β2glycoproteinI in terms of risk of thrombosis and pregnancy complications in patients with antiphospholipid syndrome. To obtain direct evidence for the pathogenic role of anti-domain 1 or anti-domain 4/5 antibodies, we analysed the in vivo pro-coagulant effect of two groups of 5 serum IgG each reacting selectively with domain 1 or domain 5 in LPS-treated rats. Antibody-induced thrombus formation in mesenteric vessels was followed by intravital microscopy and vascular deposition of β2glycoproteinI, human IgG and C3 was analyzed by immunofluorescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.198119DOI Listing
November 2018
9 Reads

PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome.

Front Immunol 2018 22;9:2413. Epub 2018 Oct 22.

Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom.

APS is an autoimmune disease in which antiphospholipid antibodies (aPL) cause vascular thrombosis and pregnancy morbidity. In patients with APS, aPL exert pathogenic actions by binding serum beta-2-glycoprotein I (β2GPI) via its N-terminal domain I (DI). We previously showed that bacterially-expressed recombinant DI inhibits biological actions of IgG derived from serum of patients with APS (APS-IgG). Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.02413
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.02413DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204385PMC
October 2018
13 Reads

Zonal cortical scarring and tubular thyroidization in kidney biopsies of patients with SLE-histologic indicator for antiphospholipid antibodies.

Lupus 2018 Dec 7;27(14):2236-2244. Epub 2018 Nov 7.

2 Department of Pathology, Division of Renal and Transplant Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Antiphospholipid antibody syndrome (APS) is an acquired prothrombotic autoimmune disease caused by the presence of antibodies against anionic phospholipids or plasma proteins bound to phospholipids on cell membranes. It can be a primary disease or secondary to other autoimmune diseases, most commonly systemic lupus erythematosus (SLE). Laboratory testing for antiphospholipid antibodies (aPL) may be only transiently positive, so APS could be missed until a catastrophic thrombotic episode or pregnancy morbidity occurs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203318809177DOI Listing
December 2018
8 Reads

Antiphospholipid syndrome: state of the art on clinical practice guidelines.

RMD Open 2018 18;4(Suppl 1):e000785. Epub 2018 Oct 18.

Rheumatology and Clinical Immunology Unit, Civil Hospital, Brescia, Italy.

Antiphospholipid syndrome (APS) is a rare disease characterised by venous and/or arterial thrombosis, pregnancy complications and the presence of specific autoantibodies called antiphospholipid antibodies. This review aims to identify existing clinical practice guidelines (CPG) as part of the ERN ReCONNET project, aimed at evaluating existing CPGs or recommendations in rare and complex diseases. Seventeen papers providing important data were identified; however, the literature search highlighted the scarceness of reliable clinical data to develop CPGs. Read More

View Article

Download full-text PDF

Source
http://rmdopen.bmj.com/lookup/doi/10.1136/rmdopen-2018-00078
Publisher Site
http://dx.doi.org/10.1136/rmdopen-2018-000785DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203101PMC
October 2018
30 Reads

Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women.

Arthritis Res Ther 2018 Nov 6;20(1):249. Epub 2018 Nov 6.

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France.

Objective: Although one of the three obstetric manifestations of antiphospholipid syndrome (APS) is intrauterine fetal death (IUFD), little is known about it in this context. We report the first large series of patients with APS and IUFD.

Methods: We retrospectively analyzed the history and clinical data of women at four French hospitals. Read More

View Article

Download full-text PDF

Source
https://arthritis-research.biomedcentral.com/articles/10.118
Publisher Site
http://dx.doi.org/10.1186/s13075-018-1745-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235231PMC
November 2018
6 Reads

[Clinical study of maternal and infant outcomes in patients with lupus nephritis complicated with pregnancy].

Zhonghua Yi Xue Za Zhi 2018 Oct;98(37):2982-2986

Department of Rheumatology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.

To investigate the outcomes and associated factors for adverse pregnancy outcomes (APO) in pregnant patients with lupus nephritis (LN). The clinical data of 139 LN pregnant patients from from 2009 to 2017 in the First Affiliated Hospital of Sun Yat-sen University were analyzed retrospectively. Totally, 105 LN were diagnosed before pregnancy and 34 were newly diagnosed during pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0376-2491.2018.37.006DOI Listing
October 2018
1 Read

Clinical profiles and risk assessment in patients with antiphospholipid antibodies.

Expert Rev Clin Immunol 2019 Jan 13;15(1):73-81. Epub 2018 Nov 13.

a Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine , Hokkaido University , Sapporo , Japan.

Introduction: Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia associated with the presence of persistent antiphospholipid antibodies (aPL). Owing to recent studies, not only APS patients but also incidentally-identified, asymptomatic aPL carriers are able to be stratified in terms of the risk of future thrombotic events, according to the variety and the titer of positive aPL tests and to the non-thrombotic, aPL-associated clinical manifestations. Areas covered: Here, we critically review (1) criteria manifestations of APS, (2) non-criteria manifestations of APS, (3) risk assessment in patients with APS and in aPL carriers, and (4) the potential role of primary thrombosis prophylaxis in aPL carriers. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1543025DOI Listing
January 2019
2 Reads

Antiphospholipid syndrome and pregnancy.

G Ital Dermatol Venereol 2018 Oct 29. Epub 2018 Oct 29.

Department of Surgical, Microsurgical and Medical Sciences, Dermatology, University of Sassari, Sassari, Italy.

Antiphospholipid syndrome (APS) is an autoimmune thrombophilic condition characterized by the onset of venous and/or arterial thrombosis, often multiple, and pregnancy morbidity in a background of antiphospholipid antibodies (aPL) positivity. Some patients can be carrier of aPL with no clinical symptoms, in other cases clinical manifestation can range from the classical presentation to an acute life-threatening condition named Catastrophic APS. APS can be considered as primary or associated to other disease, however pregnancy acts as a triggering factor on a susceptible background that lead to the clinical manifestations through immunological and non-immunological mechanism. Read More

View Article

Download full-text PDF

Source
https://www.minervamedica.it/index2.php?show=R23Y9999N00A181
Publisher Site
http://dx.doi.org/10.23736/S0392-0488.18.06152-7DOI Listing
October 2018
10 Reads

Obstetric antiphospholipid syndrome.

Lupus Sci Med 2018 25;5(1):e000197. Epub 2018 Sep 25.

Unit of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

The present clinical and laboratory classification criteria for antiphospholipid syndrome (APS) were established in Sydney, Australia, in 2006. In this review, we focus on the obstetric subset of APS (OAPS), defined by persistent positivity for antiphospholipid antibodies together with either early recurrent pregnancy loss, early fetal death, stillbirth or premature birth <34 gestational weeks due to pre-eclampsia, eclampsia and placental insufficiency. It is important to diagnose these cases since most women suffering from OAPS can, when given appropriate treatment, have successful pregnancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/lupus-2016-000197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195166PMC
September 2018
18 Reads

Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I.

Front Immunol 2018 28;9:2244. Epub 2018 Sep 28.

Imperial College Vascular Sciences National Heart & Lung Institute, Imperial Centre for Translational and Experimental Medicine (ICTEM), London, United Kingdom.

Antiphospholipid antibodies (aPL), the serological hallmark of antiphospholipid syndrome (APS), are a heterogeneous group of autoantibodies raised against circulating blood proteins. Of these proteins, the phospholipid-binding b2-glycoprotein I (β2GPI) is considered to be the main autoantigen in APS. Indeed, IgG antibodies targeting b2GPI (ab2GPI) directly cause both thrombosis and pregnancy morbidity in several mouse models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.02244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173128PMC
September 2018
2 Reads

Severe Preeclampsia, Antiphospholipid Syndrome, and Ulnar Artery Thrombosis in a Teenage Pregnancy: A Rare Association.

Case Rep Obstet Gynecol 2018 18;2018:1794723. Epub 2018 Sep 18.

University Unit of Obstetrics and Gynaecology, Teaching Hospital, Mahamodara, Galle, Sri Lanka.

Antiphospholipid syndrome (APS) is associated with vascular thrombosis and pregnancy complications. It causes recurrent miscarriage and it is associated with other adverse pregnancy outcomes such as preterm delivery, intrauterine growth restriction, preeclampsia, and HELLP syndrome. Obstetric morbidity is one of the major manifestations of APS with a wide variety of clinical manifestations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1794723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167596PMC
September 2018
1 Read

HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.

Autoimmun Rev 2018 Dec 12;17(12):1153-1168. Epub 2018 Oct 12.

Istituto Auxologico Italiano, IRCCS, Laboratory of Immunorheumatology, Milan, Italy.

The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972183022
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2018.05.012DOI Listing
December 2018
31 Reads
7.933 Impact Factor

Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: A case report.

Medicine (Baltimore) 2018 Oct;97(40):e12584

Department of Obstetrics and Gynecology, IRCCS Ospedale San Raffaele, Milan, Italy.

Rationale: Hypercoagulability and pregnancy morbidity are hallmarks of the antiphospholipid syndrome (APS). Catastrophic antiphospholipid syndrome (CAPS) is a potentially life-threatening omplication of APS, with widespread acute thrombotic microangiopathy (TMA) that can be precipitated by pregnancy and delivery and result in multiorgan damage. Unrestrained activation of the complement cascade is involved, favoring endothelial activation, tissue factor expression by leukocytes, and platelet aggregation. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005792-201810050-0003
Publisher Site
http://dx.doi.org/10.1097/MD.0000000000012584DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200483PMC
October 2018
5 Reads

Management of antiphospholipid syndrome.

Ann Rheum Dis 2019 Feb 3;78(2):155-161. Epub 2018 Oct 3.

Department of Rheumatology, Dubai Hospital, Dubai, United Arab Emirates

Antiphospholipid syndrome, also known as 'Hughes Syndrome', is an autoimmune disease characterised by a set of clinical manifestations, almost all of which are direct or indirect sequelae of a hypercoagulable state involving the venous, and to a lesser extent the arterial vasculature. The incidence and prevalence of antiphospholipid syndrome are estimated at approximately 5 de novo cases per 100 000 per year and 40-50 cases per 100 000 individuals, respectively. The clinical spectrum of antiphospholipid syndrome involves haematological (thrombocytopaenia, venous thrombosis), obstetrical (recurrent pregnancy loss), neurological (stroke, transient ischaemic attack, migraine, seizures, cognitive dysfunction, chorea, transverse myelitis, multiple sclerosis), cardiovascular (cardiac valve disease), dermatological (livedo reticularis and racemosa, skin ulceration and necrosis), renal (glomerulonephritis, renal thrombotic microangiopathy) and orthopaedic (avascular necrosis of bones, non-traumatic fractures) manifestations, among others. Read More

View Article

Download full-text PDF

Source
http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2018-21384
Publisher Site
http://dx.doi.org/10.1136/annrheumdis-2018-213846DOI Listing
February 2019
5 Reads

The anti-thrombotic effects of vitamin D and their possible relationship with antiphospholipid syndrome.

Lupus 2018 Dec 3;27(14):2181-2189. Epub 2018 Oct 3.

9 Department of Autoimmune Diseases, Institut Clínic de Medicina I Dermatologia, Barcelona, Spain.

The importance of the immunomodulatory effects of vitamin D has recently been associated with autoimmune and chronic inflammatory diseases. Vitamin D deficiency has been linked to the development of autoimmune conditions. Antiphospholipid syndrome is an autoimmune disease characterized by thrombotic events and obstetric complications in patients with antiphospholipid antibodies. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0961203318801520
Publisher Site
http://dx.doi.org/10.1177/0961203318801520DOI Listing
December 2018
2 Reads

Thrombotic Microangiopathies with Rheumatologic Involvement.

Rheum Dis Clin North Am 2018 11 7;44(4):635-649. Epub 2018 Sep 7.

Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University, 2150 Pennsylvania Avenue, Washington, DC 20037, USA. Electronic address:

Thrombotic microangiopathies are heterogeneous disorders characterized by microangiopathic hemolytic anemia with thrombocytopenia and renal injury. There are a variety of causes, including metabolic disorders, infections, medications, complement disorders, pregnancy, malignancy, and autoimmune disorders. This review focuses on renal thrombotic microangiopathy in the setting of rheumatologic diseases. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0889857X183006
Publisher Site
http://dx.doi.org/10.1016/j.rdc.2018.06.010DOI Listing
November 2018
31 Reads

Transient EDTA-Dependent Pseudothrombocytopenia Phenomenon in a Patient with Antiphospholipid Syndrome.

Clin Lab 2018 Sep;64(9):1581-1583

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with arterial/venous thrombosis and pregnancy loss; thrombocytopenia is another common manifestation of APS. In the present study, we discovered a transient ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia (EDTA-PTCP) phenomenon in APS, which has not yet been reported in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7754/Clin.Lab.2018.180337DOI Listing
September 2018
8 Reads

Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study.

BJOG 2018 Sep 17. Epub 2018 Sep 17.

Department of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.

Objective: To evaluate the subsequent rate of thrombosis among women with obstetric antiphospholipid syndrome (Ob-APS) in a multicentre database of antiphospholipid antibody (aPL)-positive patients, and the clinical utility of the adjusted Global Antiphospholipid Syndrome Score (aGAPSS), a validated tool to assess the likelihood of developing new thrombosis, in this group of patients.

Design: Retrospective study.

Setting: The Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1471-0528.15469DOI Listing
September 2018
1 Read

Connecting links between genetic factors defining ovarian reserve and recurrent miscarriages.

J Assist Reprod Genet 2018 Dec 15;35(12):2121-2128. Epub 2018 Sep 15.

Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, U.P., 226014, India.

Purpose: Approximately 1-2% of the women faces three or more successive spontaneous miscarriages termed as recurrent miscarriage (RM). Many clinical factors have been attributed so far to be the potential risk factors in RM, including uterine anomalies, antiphospholipid syndrome, endocrinological abnormalities, chromosomal abnormalities, and infections. However, in spite of extensive studies, reviews, and array of causes known to be associated with RM, about 50% cases encountered by treating physicians remains unknown. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10815-018-1305-3
Publisher Site
http://dx.doi.org/10.1007/s10815-018-1305-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289926PMC
December 2018
15 Reads

Antiphospholipid syndrome - an update.

Authors:
Birgit Linnemann

Vasa 2018 10 12;47(6):451-464. Epub 2018 Sep 12.

1 Division of Angiology, East Bavarian Center of Vascular Medicine, University Hospital Regensburg, Regensburg, Germany.

Antiphospholipid syndrome (APS) is an autoantibody-mediated acquired thrombophilia. It is characterized by the presence of antiphospholipid antibodies (APL) that are directed against phospholipid-binding plasma proteins, such as beta-2-glycoprotein I (b2GPI). Its main manifestations are recurrent vascular thromboses (so-called "thrombotic APS") and pregnancy complications ("obstetric APS"). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1024/0301-1526/a000723DOI Listing
October 2018
16 Reads

Modulation of trophoblast function by concurrent hyperglycemia and antiphospholipid antibodies is in part TLR4-dependent.

Am J Reprod Immunol 2018 Oct 8;80(4):e13045. Epub 2018 Sep 8.

Department of Obstetrics, Gynecology & Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut.

Problem: While diabetes and APS are individually associated with increased risk of poor perinatal outcomes, in particular preeclampsia, recent studies have demonstrated an association between concurrent aPL and diabetes leading to an increased risk of pregnancy morbidity. Hyperglycemia and aPL have independently been shown to alter human trophoblast function by inducing a pro-inflammatory, anti-angiogenic, and antimigratory response. However, little is known about the effects of concurrent hyperglycemia and aPL on trophoblast function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aji.13045DOI Listing
October 2018
4 Reads

Anticardiolipin (aCL) in sera from periodontitis subjects activate Toll-like receptor 4 (TLR4).

PLoS One 2018 7;13(9):e0203494. Epub 2018 Sep 7.

Department of Periodontics, Virginia Commonwealth University School of Dentistry, Richmond, Virginia, United States of America.

Anticardiolipin antibodies (aCL) have been reported to be present in 15-20% of sera from subjects with periodontitis at concentrations exceeding those found in 95% of the healthy adult population. These antibodies, albeit at concentrations exceeding those generally found in periodontitis subjects, are typically present in patients with the antiphospholipid syndrome (APS), an autoimmune disease characterized by thrombosis and recurrent pregnancy loss. aCL from APS patients are proinflammatory and can activate trophoblasts, macrophages, and platelets via cell-surface interactions with their target antigen beta-2-glycoprotein-I (β2GPI). Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0203494PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128564PMC
September 2018
2 Reads

Primary antiphospholipid syndrome associated Liebman-Sachs endocarditis leading to diffuse alveolar hemorrhage: A case report.

Respir Med Case Rep 2018 24;25:181-183. Epub 2018 Aug 24.

Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, USA.

A 26 year old female presented for recurrent blood tinged sputum during the previous year with development of frank hemoptysis three days prior to admission. Diffuse alveolar hemorrhage (DAH) was confirmed with serial lavages. The patient had no history of autoimmune disease, vascular thrombosis or pregnancy morbidity including miscarriages or pre-eclampsia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2018.08.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125762PMC
August 2018
2 Reads

What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?

Immunol Res 2018 10;66(5):577-583

Hemostasis and Thrombosis Laboratory, Hospital of Infectious Diseases "Dr. Francisco J. Muñiz", Uspallata 2272, C1282AEN, City of Buenos Aires, Argentina.

Serological risk factors are the most important determinant in predicting unsuccessful pregnancy in obstetric antiphospholipid antibodies syndrome (OAPS) despite conventional treatment. It is not clear if changes in the profile of antiphospholipid antibodies (aPL) during pregnancy modify the risk associated with a poor response to conventional treatment. The aim of our study was to compare the value of a serological tag for aPL obtained before and during the first trimester of pregnancy to predict the response to conventional treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12026-018-9024-5DOI Listing
October 2018
2 Reads

Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant).

Curr Rheumatol Rep 2018 Aug 20;20(10):62. Epub 2018 Aug 20.

Department of Autoimmune Diseases, Hospital Clinic, Villarroel, 170, 08036, Barcelona, Catalonia, Spain.

Purpose Of Review: The antiphospholipid syndrome (APS) is characterized by the development of thrombotic events and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). An infectious etiology for this syndrome has been postulated. The present review is aimed to summarize recent evidence about the role of infections and vaccines in the pathogenesis of the APS (including its catastrophic variant). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11926-018-0773-xDOI Listing
August 2018
15 Reads

Reimagining the antiphospholipid syndrome, an enigmatic thrombophilic disorder, through the looking glass of microscopic imaging.

Histochem Cell Biol 2018 Nov 18;150(5):529-543. Epub 2018 Aug 18.

Department of Pathology and Laboratory Medicine, and Microscopy Imaging Center, Larner College of Medicine, University of Vermont, 89 Beaumont Avenue, Burlington, VT, 05405, USA.

The antiphospholipid syndrome (APS) is an autoimmune thrombophilic disorder that was described as a diagnostic entity over 30 years ago. And yet the pathogenic mechanisms that are responsible for its clinical manifestations remain to be definitively established. The syndrome is defined by (1) the concurrence of vascular thrombosis and/or pregnancy complications together with (2) positivity for immunoassays and coagulation tests that were derived from clinical observations of two anomalous laboratory test results-specifically, false positivity for syphilis infection in uninfected individuals and the finding of inhibitors of blood coagulation in patients who lacked any bleeding tendencies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00418-018-1709-2DOI Listing
November 2018
3 Reads

Antiphospholipid syndrome: An update on risk factors for pregnancy outcome.

Autoimmun Rev 2018 Oct 15;17(10):956-966. Epub 2018 Aug 15.

Department of Obstetrics, Gynaecology and Pediatrics, F.Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy.

Background: The optimal treatment of women with primary antiphospholipid syndrome (APS) is still debated. About 20-30% of women with APS remain unable to give birth to healthy neonates despite conventional treatment, consisting of prophylactic-dose heparin and low-dose aspirin. These cases are defined "refractory obstetric APS". Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.03.018DOI Listing
October 2018
14 Reads

Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-β2glycoprotein I antibody detection assays.

J Thromb Haemost 2018 Oct 24;16(10):2016-2023. Epub 2018 Aug 24.

Coagulation Laboratory, Department of Diagnostic Sciences, Ghent University Hospital, Gent, Belgium.

Essentials Triple-positivity is associated with a high risk for a first thrombotic event and recurrence. Identification of triple-positives is dependent on the solid phase assay used. In triple-positivity, IgM only adds value in thrombotic risk stratification together with IgG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14261DOI Listing
October 2018
1 Read